神经退行性疾病的认知和神经成像:一个队列研究设计与初步发现
Akram A Hosseini1,2,3, Beili Shao1,3, Abigail Rebecca Lee1
1Department of Neurology, Research and Innovation, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom.
medRxiv : the preprint server for health sciences
|July 15, 2025
概括
早发性认知衰退 (EOCD) 显示出显著的异质性,往往被误诊. 神经成像和脑脊液生物标志物提高了EOCD的诊断准确度,而不是晚发性认知衰退 (LOCD),揭示了LOCD的不同形状和更高的死亡率.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 老年学是一门学科.
背景情况:
- 痴呆症在各个年龄组中表现出显著的异质性,早期认知衰退 (EOCD) 呈现出独特的诊断和管理挑战.
- 神经退行性疾病认知和神经成像 (CogNID) 研究解决了认知障碍诊断和生物标志物实用性的复杂性.
研究的目的:
- 在一个具有认知障碍的多元群体中,描述临床,认知,神经成像和生物标记特征.
- 专注于诊断复杂性,生物标志物实用性和早期发病 (EOCD) 和晚期认知衰退 (LOCD) 之间的死亡率差异.
主要方法:
- 来自NHS记忆诊所的429名参与者的前性队列研究,包括EOCD (<65岁) 和LOCD (≥65岁) 组.
- 数据收集包括结构化认知评估,神经成像 (MRI/CT) 和脑脊液 (CSF) 生物标志物评估.
- 诊断是通过多学科的共识建立的.
主要成果:
- EOCD包括81.4%的队列 (n=349).
- 阿尔茨海默病的生物标志物在36.4%的经过测试的EOCD参与者中被发现;功能性认知障碍 (FCD) 在EOCD中更为普遍 (22.3%对5.0%).
- 在LOCD组中,死亡率更高 (11.3%对比4.6%).
结论:
- 该CogNID研究强调了认知障碍的诊断异质性,特别是在年轻人中.
- 整合神经成像和CSF生物标志物可以提高诊断精度,并将EOCD与LOCD表型区分开来.
- 研究结果强调需要协调诊断方案,可访问的生物标志物,以及在痴呆症研究中的包容性招聘.
更多相关视频
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
17.5K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.1K
相关概念视频
Alzheimer's Disease: Overview
673
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
673
Alzheimer's Disease: Treatment
263
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
263
